Tolerability and Positive Efficacy Results after Subcutaneous Immunotherapy with Parietaria Judaica Depot Extract

Authors:

Abstract
Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion:P. judaica subcutaneous immunotherapy (Allergovac((R)) depot ROXALL Medicina Espana S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.
Funding Information
  • ROXALL Medicina España S.A., Zamudio

This publication has 34 references indexed in Scilit: